Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer
OBJECTIVES We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans. METHODS Prostate cancer diagnoses in the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Us...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Epidemiology
2018-08-01
|
| Series: | Epidemiology and Health |
| Subjects: | |
| Online Access: | http://www.e-epih.org/upload/pdf/epih-40-e2018040.pdf |
| _version_ | 1829494925808369664 |
|---|---|
| author | Kyungsuk Jung Jong Chul Park Hyunseok Kang Johann Christoph Brandes |
| author_facet | Kyungsuk Jung Jong Chul Park Hyunseok Kang Johann Christoph Brandes |
| author_sort | Kyungsuk Jung |
| collection | DOAJ |
| description | OBJECTIVES We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans. METHODS Prostate cancer diagnoses in the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as 2 diagnoses made within 1 year, were excluded from the analysis. Cancer-free survival was estimated using the Kaplan-Meier method and hazard ratios were estimated using Cox proportional hazard models. RESULTS Among the 63,141 identified patients with prostate cancer, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and the median follow-up period was 28 months. ADT use was associated with longer lung cancer-free survival in prostate cancer patients (log-rank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15, 21, and 24% after 1, 2, and 3 years, respectively. CONCLUSIONS ADT in prostate cancer patients may be associated with decreased second primary lung cancer risk among US veterans. |
| first_indexed | 2024-12-16T07:01:40Z |
| format | Article |
| id | doaj.art-9c491925de21413fbc7b4e4c9dfa84b1 |
| institution | Directory Open Access Journal |
| issn | 2092-7193 |
| language | English |
| last_indexed | 2024-12-16T07:01:40Z |
| publishDate | 2018-08-01 |
| publisher | Korean Society of Epidemiology |
| record_format | Article |
| series | Epidemiology and Health |
| spelling | doaj.art-9c491925de21413fbc7b4e4c9dfa84b12022-12-21T22:40:09ZengKorean Society of EpidemiologyEpidemiology and Health2092-71932018-08-014010.4178/epih.e2018040993Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancerKyungsuk Jung0Jong Chul Park1Hyunseok Kang2Johann Christoph Brandes3 Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Oncology, Atlanta Veterans Affairs Medical Center, Atlanta, GA, USAOBJECTIVES We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans. METHODS Prostate cancer diagnoses in the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as 2 diagnoses made within 1 year, were excluded from the analysis. Cancer-free survival was estimated using the Kaplan-Meier method and hazard ratios were estimated using Cox proportional hazard models. RESULTS Among the 63,141 identified patients with prostate cancer, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and the median follow-up period was 28 months. ADT use was associated with longer lung cancer-free survival in prostate cancer patients (log-rank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15, 21, and 24% after 1, 2, and 3 years, respectively. CONCLUSIONS ADT in prostate cancer patients may be associated with decreased second primary lung cancer risk among US veterans.http://www.e-epih.org/upload/pdf/epih-40-e2018040.pdfLung neoplasmsProstatic neoplasmsAndrogen antagonistsHormonesVeterans |
| spellingShingle | Kyungsuk Jung Jong Chul Park Hyunseok Kang Johann Christoph Brandes Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer Epidemiology and Health Lung neoplasms Prostatic neoplasms Androgen antagonists Hormones Veterans |
| title | Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer |
| title_full | Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer |
| title_fullStr | Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer |
| title_full_unstemmed | Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer |
| title_short | Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer |
| title_sort | androgen deprivation therapy is associated with decreased second primary lung cancer risk in the united states veterans with prostate cancer |
| topic | Lung neoplasms Prostatic neoplasms Androgen antagonists Hormones Veterans |
| url | http://www.e-epih.org/upload/pdf/epih-40-e2018040.pdf |
| work_keys_str_mv | AT kyungsukjung androgendeprivationtherapyisassociatedwithdecreasedsecondprimarylungcancerriskintheunitedstatesveteranswithprostatecancer AT jongchulpark androgendeprivationtherapyisassociatedwithdecreasedsecondprimarylungcancerriskintheunitedstatesveteranswithprostatecancer AT hyunseokkang androgendeprivationtherapyisassociatedwithdecreasedsecondprimarylungcancerriskintheunitedstatesveteranswithprostatecancer AT johannchristophbrandes androgendeprivationtherapyisassociatedwithdecreasedsecondprimarylungcancerriskintheunitedstatesveteranswithprostatecancer |